Physician profile
Bert Chronister
NPI 1104938430
$856.93
in general payments reported to CMS, 2019-2025
16 companies · $17.19 in 2025
The $17.19 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.50 · 2020: $65.70 · 2021: $170 · 2022: $224 · 2023: $188 · 2024: $127 · 2025: $17.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $332.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $202.29 | 2019-2024 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals Lp | $133.15 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $89.84 | 2021-2022 | |
| Lilly USA, LLC | $71.19 | 2021-2024 | Mounjaro |
| Sanofi Pasteur INC. | $64.16 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $46.95 | 2022-2025 | |
| Pfizer INC. | $38.93 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $36.76 | 2022 | |
| Abbvie INC. | $36.03 | 2021-2023 | Mavyret |
| Novo Nordisk INC | $33.01 | 2022-2024 | Wegovy |
| Amarin Pharma, INC. | $24.09 | 2021 | |
| Daiichi Sankyo INC. | $19.70 | 2020 | |
| Edwards Lifesciences Corporation | $19.42 | 2023 | Sapien 3 Ultra Resilia |
| Idorsia Pharmaceuticals US INC | $13.92 | 2023 | Quviviq |
| Next Science LLC | $13.84 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $13.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bert Chronister listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.